Balanced news tone
News Sentiment
GLUE sentiment intelligence
Monte Rosa Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
-4.8% over one week, +26.4% over four weeks, trend active, and materially above fair value.
Monte Rosa Therapeutics, Inc. $GLUE is Versant Venture Management LLC's Largest Position
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 29 Jun 2026 22:50
- Source
- Motley Fool
Does Monte Rosa Therapeutics' (GLUE) Shift Into Russell Growth Indices Recast Its Biotech Risk Profile?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 01:21
- Source
- simplywall.st
Monte Rosa (GLUE) CMO sells 41,845 shares after exercising options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.8% - Should You Buy?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- MarketBeat
GLUE (NASDAQ: GLUE) insider files Form 144 to sell 11,845 shares on 06/23/2026
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
Monte Rosa (NASDAQ: GLUE) CSO sells 3,000 shares under 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Jun 2026 18:00
- Source
- Insider Monkey
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 11:00
- Source
- GlobeNewswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 May 2026 00:24
- Source
- Simply Wall St.
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 07 May 2026 15:15
- Source
- Zacks
Monte Rosa Therapeutics: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 13:18
- Source
- Associated Press
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 11:00
- Source
- GlobeNewswire
MONTE ROSA THERAPEUTICS ($GLUE) Releases Q1 2026 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Quiver Quantitative
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 21 Apr 2026 17:53
- Source
- Motley Fool
What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today
- Tone
- Negative 34/100
- Event
- Analyst action
- Published
- 21 Apr 2026 07:00
- Source
- simplywall.st
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- simplywall.st
The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Feb 2026 08:00
- Source
- simplywall.st
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jan 2026 08:00
- Source
- GlobeNewswire
Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Sep 2025 07:00
- Source
- Seeking Alpha
Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Oct 2024 07:00
- Source
- BioPharm International